Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$37.39 USD
+0.51 (1.38%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $37.38 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
APLS 37.39 +0.51(1.38%)
Will APLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Other News for APLS
Roche failure removes potential downside for Apellis, says Baird
Apellis Pharmaceuticals (APLS) Receives a Buy from Stifel Nicolaus
Apellis Pharmaceuticals Strengthened Market Position and Buy Rating Following Competitor’s Clinical Failure
Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and EDAP TMS (EDAP)